JD
Therapeutic Areas
Acumen Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Sabirnetug (ACU193) - Intravenous (IV) | Early Alzheimer's Disease | Phase 2 |
| Sabirnetug (ACU193) - Subcutaneous (SC) | Early Alzheimer's Disease | Phase 1 |
| Enhanced Brain Delivery (EBD™) [TfR-Brain transporter + AβO mAb] | Early Alzheimer's Disease | Preclinical |
Leadership Team at Acumen Pharmaceuticals
DO
Daniel O’Connell
Chief Executive Officer
ES
Eric Siemers, MD
Chief Medical Officer
MZ
Matthew Zuga
Chief Financial Officer & Chief Business Officer
RB
Russell Barton, MS
Chief Operating Officer
AS
Amy Schacterle, PhD
Chief Regulatory Officer & Head of Quality
DM
Derek Meisner
Chief Legal Officer, Corporate Secretary
JB
Julie Bockenstette
Chief People Officer
LS
Lian Schenck, MS
Senior Vice President, Head of CMC
PS
Paul Shughrue, PhD
Vice President, Program Leader and Head of Research
LR
Laura Rosen, MD, PhD
Senior Vice President, Clinical Development